Association of ACE, VEGF and CCL2 gene polymorphisms with Henoch–Schönlein purpura and an evaluation of the possible interaction effects of these loci in HSP patients

Tahereh Mohammadian1,8, C Mortaza Bonyadi2, A–F, Elahe Nabat1, B, Mandana Rafeey3, B

1 Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
2 University of Tabriz
3 Liver and Gastrointestinal Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;
D – writing the article; E – critical revision of the article; F – final approval of article

Abstract

Background. Henoch–Schönlein purpura (HSP) is a multisystem, small vessel, leucocytoclastic vasculitis. It is predominantly a childhood vasculitis, rarely reported in adults. Studies have shown that several different genetic factors such as genes involved in inflammatory system and renin-angiotensin system (RAS) are important in the pathogenesis of Henoch–Schönlein purpura.

Objectives. The purpose of this study was to evaluate the independent effect of 3 gene polymorphisms including CCL2-2518 C/T, VEGF-634G/C and ACE(I/D) with HSP disease and their possible joint interactions in developing the disease.

Material and methods. In this case-control study 47 HSP cases and 74 unrelated healthy controls were enrolled for evaluation. All individuals were genotyped for CCL2-2518C/T, VEGF-634G/C and ACE(I/D) gene polymorphisms. The possible association of these polymorphisms with susceptibility to develop HSP disease independently and in different joint combinations was evaluated.

Results. The frequencies of TT genotype and T allele of CCL2-2518C/T gene polymorphism and CC genotype and C allele of VEGF-634G/C gene polymorphism were significantly high in HSP children (p-values = 0.005 and = 0.007 respectively). Interestingly, studying the joint interaction of these 2 genotypes (CC genotype of VEGF G-634C and TT genotype of CCL2 C-2518T) in this cohort showed a more significant effect in the development of the disease (p < 0.000, OR = 6.009). The frequency of TT genotype of CCL2 gene when combined with II genotype of ACE gene in HSP children was significantly higher (p < 0.000, OR = 4.213).

Conclusions. The results of this pilot study provide evidence of the possible gene—gene interaction effects of CCL2, VEGF and ACE genes in developing HSP disease.

Key words: CCL2, VEGF, Henoch–Schönlein purpura, gene—gene interaction effect, ACE
Henoch–Schönlein purpura (HSP) is a leukocytoclastic vasculitis of small blood vessels usually occurring between 3 and 15 years but it could be developed at any age. This systemic vasculitis is characterized by palpable purpura, arthritis or arthralgias, gastrointestinal and renal involvement.1,2

It has been shown that multiple different genes and their interactions with environmental factors are involved in the susceptibility to HSP. Therefore, genetic background is an important factor in the pathogenesis of this immune-mediated inflammatory disease.4

Inflammatory mediators such as transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF) and some pro-inflammatory chemokines increase in the serum of HSP patients.5–7

The MCP-1/CCL2 produced by macrophages, endothelia and some other cells is chemotactic cytokine that has important role in immune-regulatory and inflammatory processes by attracting monocytes to the region of inflammation. MCP-1-2518 polymorphism is located in promoter region of the gene and its role in the development of HSP disease has been evaluated previously.9

Vascular endothelial growth factor (VEGF) is a cytokine with angiogenic activity which could have a crucial role in inflammatory reaction in different disorders. It has been proposed that VEGF-634G/C polymorphism, which affects the expression level of the gene, could have an association with the development of the disease.10

Angiotensin I-converting enzyme (ACE) is a key component of the renin-angiotensin system. This system regulates vascular homeostasis and inflammation. Increasing the level of ACE leads to vascular inflammation due to cytokine release.11 Polymorphism of the ACE gene (I/D) and its role in HSP disease has been studied in patients from different populations.12,13

Considering that HSP disease is a complex disease involving different genetic factors, we planned to evaluate the possible associations of these polymorphisms with the susceptibility to HSP independently and in different joint combinations.

Genetic analysis

Genomic DNA was extracted from whole blood according to standard DNA extraction protocol.14 Each individual was genotyped for CCL2 -2518 C/T and VEGF -634 G/C polymorphisms by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) as described previously.15,16 In brief, to genotype for CCL2 -2518, the PCR product was digested by PvuII restriction enzyme. The PCR product from individuals with C/C genotype was digested into 121 & 172bp. In individuals with T/T genotype 293bp, the PCR product was left intact.15 In order to genotype for VEGF -634 polymorphism, the amplified fragments were digested with BsmI restriction endonuclease. The GG genotype was cut into two fragments of 250bp and 93bp, while the CC genotype displayed a single fragment of 343bp.16

The I/D polymorphism in ACE gene was determined by applying PCR as described previously.17

Table 1. Genotype and allele distributions of the patients and controls in 3 polymorphisms

<table>
<thead>
<tr>
<th>Genotypes &amp; alleles</th>
<th>N (%)</th>
<th>p-value</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF-634G/C case-control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>7 (14.89)</td>
<td>19 (25.67)</td>
<td>0.021*</td>
</tr>
<tr>
<td>GC</td>
<td>27 (57.45)</td>
<td>45 (60.81)</td>
<td>0.347</td>
</tr>
<tr>
<td>CC</td>
<td>13 (27.66)</td>
<td>10 (13.51)</td>
<td>0.007*</td>
</tr>
<tr>
<td>G</td>
<td>41 (43.62)</td>
<td>83 (56.08)</td>
<td>0.036*</td>
</tr>
<tr>
<td>C</td>
<td>53 (56.38)</td>
<td>65 (43.92)</td>
<td>0.030*</td>
</tr>
<tr>
<td>CCL2 -2518C/T case-control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>1 (2.13)</td>
<td>8 (10.81)</td>
<td>0.010*</td>
</tr>
<tr>
<td>CT</td>
<td>15 (31.91)</td>
<td>31 (41.89)</td>
<td>0.057*</td>
</tr>
<tr>
<td>TT</td>
<td>31 (65.95)</td>
<td>35 (47.29)</td>
<td>0.005*</td>
</tr>
<tr>
<td>C</td>
<td>17 (18.08)</td>
<td>47 (31.75)</td>
<td>0.018*</td>
</tr>
<tr>
<td>T</td>
<td>77 (81.91)</td>
<td>101 (68.24)</td>
<td>0.015*</td>
</tr>
<tr>
<td>ACE I/D case-control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>14 (29.79)</td>
<td>16 (21.62)</td>
<td>0.109</td>
</tr>
<tr>
<td>ID</td>
<td>16 (34.04)</td>
<td>28 (37.84)</td>
<td>0.295</td>
</tr>
<tr>
<td>DD</td>
<td>17 (36.17)</td>
<td>30 (40.54)</td>
<td>0.336</td>
</tr>
<tr>
<td>I</td>
<td>44 (46.81)</td>
<td>60 (40.54)</td>
<td>0.210</td>
</tr>
<tr>
<td>D</td>
<td>50 (53.19)</td>
<td>88 (59.46)</td>
<td>0.183</td>
</tr>
</tbody>
</table>

*p-value less than 0.05.

Material and methods

Patients

The studied population consisted of 47 patients (28 males and 19 females, with a mean age of 8.14 years) who were diagnosed by specialists for HSP. The control group consisted of 74 healthy adults with no renal, vasculitic, allergic or inflammatory diseases. The majority of patients (95.74%) had palpable purpura. Gastrointestinal complications in 63.82% and joint pain in 44.68% of the patients were observed. This study was approved by the Ethics Committee of Tabriz University of Medical Science and an informed written consent was obtained from all patients’ parents.
Three-locus (TT CCL2/II ACE/ GC VEGF) joint effect was significantly different in 2 groups (p = 0.043, OR = 2.821) (Table 2).

Discussion

Different studies clearly show that genetic and non-genetic factors play important roles in the development of HSP disease. In this paper we focus on the possible interaction effects of SNPs from 3 different genes among HSP patients from Iranian Azeri Turkish population. We propose that an investigation of gene-gene interactions would expand our current understanding about the development of HSP disease. The impact of 3 different SNPs including CCL2 C-2518T, VEGF G-634C and ACE I/D was independently evaluated and their possible joint interactions were explored. Furthermore, different combinations of their genotypes were also studied in this cohort. On the basis of these results, individuals carrying CC genotype of VEGF G-634C (p = 0.007, OR = 2.448) and TT genotype of CCL2 C-2518T (p = 0.005, OR = 2.159) exhibited twice the susceptibility for developing the disease. Interestingly, studying joint interactions of these 2 genotypes (CC genotype of VEGF G-634C and TT genotype of CCL2 C-2518T) in our cohort showed that individuals with CC-TT genotype have six times increased possibility of developing the disease (p < 0.000, OR = 6.009). The association with ACE I/D gene was only found when it was joint with CCL2 -2518 gene polymorphism. II genotype of ACE in joined with TT genotype of CCL2 C-2518T showed statistically significant effect on the development of HSP disease (p < 0.000, OR = 4.213).

HSP is known as a multifactorial disease, thus the involvement of multiple SNPs from a variety of genes and their joint-interaction affecting the development of the disease is possible.

Pro-inflammatory cytokines and complement family are possible factors involved in the pathogenesis of HSP. Increased levels of VEGF have been reported in some systemic vasculitis such as Behcet’s disease and HSP. VEGF–634 G/C polymorphism of this gene has been reported as a genetic variant that may contribute to the development of the disease.5,18 Rueda et al and Zeng et al. have already reported that the frequency of VEGF-634 C allele is significantly increased in HSP patients.10,19

Yu et al.’s results showed elevations of the chemokine MCP1 in patients with acute HSP and they reported that T allele of this polymorphism was associated with the disease.9 Increased risk of developing HSP for individuals carrying both CC genotype of VEGF G-634C and TT genotype of CCL2 C-2518T indicate that there is a possible gene-gene interaction between these 2 genotypes (additive effect) and this joint effect could be either between genes or their encoded proteins.
Although some previous studies were unable to confirm any association between ACE I/D gene polymorphism and HSP disease, a study on a Chinese cohort have shown that the frequency of D allele was higher than that of control group.12,20,21

The ACE I/D SNP was not associated with HSP in our population; however, joint interaction analysis of ACE I/D and CCL2 -2518T showed a significantly higher frequency of II genotype of ACE I/D in coexistence with TT genotype of CCL2 -2518T in patients. This joint association shows the possible existence of epistasis between these two genes. Since endothelial cell activation and vasculitis of the small blood vessels occurs in HSP, RAS genes including ACE gene polymorphisms seem to be biologically and clinically relevant to the development of the disease.

CCL2 has also an important role in the development of auto-inflammatory disorders including HSP. Our study evaluates potential interaction of CCL2 and ACE genes.

This is the first pilot study that evaluated independent and joint interactions of these three polymorphisms (-2518 C/T CCL2, -634C/G VEGF and ACE I/D) in regards to the susceptibility to HSP disease.

References